Get in Touch
Talk to a Scientific Specialist to to learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical application.
Learn HowCREATE TRANSFORMATIVE MEDICINES
Translate biology insights into genetic medicines
Latest News
June 1, 2021 — We are pleased to announce that Precision NanoSystems (PNI) is joining the Danaher Life Sciences platform. Learn More
We are pleased to announce that Precision NanoSystems (PNI) is joining the Danaher Life Sciences platform.
Together with Pall Corporation and Cytiva, we will further enable development of transformative medicines that improve the lives of patients. PNI, Cytiva, and Pall Corporation offer complementary portfolios from equipment and consumables through to fully
flexible manufacturing solutions, designed for the manufacturing of genetic medicine-based therapies from discovery to commercial production. For more information, see the full press release.
-
Disease TargetBiology insights can identify target gene(s) driving disease
Genetic Medicine Toolkit
-
Choose RNA/DNA to silence, express, or edit target gene(s) -
Lipid nanoparticles (LNP) protect & deliver RNA/DNA to target cells -
Microfluidics manufactures genetic medicines seamlessly from discovery to clinic
-
Leverage world-leading expertise in genetic medicine development
mRNA & DNA-based vaccines Prophylactic & therapeutic
Infectious Disease & Oncology
Population-based to individualized
Infectious Disease & Oncology
Population-based to individualized
siRNA, mRNA, DNA, CRISPR
Silence, express, or edit genes
Focus on rare disease
Population-based to individualized
Silence, express, or edit genes
Focus on rare disease
Population-based to individualized
siRNA, mRNA, DNA, CRISPR
Immune cells including T-Cells
Focus on oncology
Autologous & allogeneic
Immune cells including T-Cells
Focus on oncology
Autologous & allogeneic
Get Started
Learn how Precision NanoSystems can help accelerate development of genetic medicines.
Flexible Access to the Toolkit and Workflows
Use the NanoAssemblr Manufacturing platform and the GenVoy Delivery platform from the Genetic Medicine Toolkit in your laboratories. Our global team is available for onsite support.
Precision has an experienced team dedicated to development of genetic medicines on behalf of our partners. Our team uses the Genetic Medicine Toolkit and Workflows to develop vaccines, gene therapies and cell therapies from idea to commercial product.
-
We are excited about this promising collaboration and hope that it will propel our work forward as the ncRNA Core Facility focuses on the non-coding RNA portions of the genome for [the] discovery of novel biomarkers and targets for therapeutics from human disease tissue and clinical trial specimens.
Frank Slack, PhD
Director of Initiative for RNA
Harvard Medical School -
Our team has been dedicated to developing safe and effective vaccines to fight against the COVID-19 pandemic. Since RNA vaccines are a disruptive technology as they do not require cell culture, utilize synthetic delivery and have a smaller manufacturing footprint, our partnership with PNI to advanc...
Read More
Xuefeng Yu, PhD
Co-founder, Chairman and CEO
CanSinoBIO -
Ajinomoto Bio-Pharma Services has audited the PNI facilities in Vancouver and has qualified PNI's NanoAssemblr GMP System and its components. We are excited to work with PNI to offer their purpose-designed manufacturing technology and unique nanomedicine expertise to our clients for the manufacture ...
Read More
Kristin Defife, PhD
Vice President and Head of US Operations
Ajinomoto Bio-Pharma Services -
We look forward to working with Precision NanoSystems to support research efforts around the discovery of novel sLNPs that we believe have the potential to significantly improve and broaden biodistribution. sLNPs represent an exciting and innovative approach in Alnylam’s advancement of proprietary L...
Read More
Kenneth Koblan, PhD
Chief Scientific Officer
Alnylam -
The scalability and reproducibility of PNI’s NanoAssemblr platform allowed us to move into GMP manufacturing with greater control over the process and increased precision in the final product compared to our previous macromixing process, allowing acceleration of our time to commercialization.
David Evans, PhD
Chief Scientific Officer
Sirnaomics -
PNI is globally renowned for their NanoAssembr suite of products that enable high quality, consistent nanoparticle formation and seamless scale up from the laboratory to GMP manufacturing for the clinic. Using their GMP System will let us meet the challenge of producing our pan-coronavirus DNA vacci...
Read More
John Lewis, PhD
Chief Executive Officer
Entos -
Our government is bringing back the vaccine manufacturing capacity that Canadians expect and need. These investments will help to ensure that Canada has modern, flexible vaccine manufacturing capabilities now and in the future. With the investments announced today, our government is helping Canadian...
Read More
Honourable François-Philippe Champagne
Minister of Innovation, Science and Industry
Government of Canada -
Of particular note is LM03PE which had IgG levels of almost 108 ng/mL. We've never seen antibody levels this high.
Comments on PNI's proprietary RNA-LNP formulations eliciting a strong immune response in an influenza challenge study
Anna Blakney, PhD
Marie Skłodowska-Curie Research Fellow
Imperial College London -
The ease, reproducibility, and the robustness of PNI’s products is amazing compared to what we previously had used, and that’s been a real enabling factor for Guide as we’ve continued to grow over the last year and a half.
Corey Sago, PhD
Chief Technology Officer
Guide Therapeutics
Sign Up and Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.